Sydney R Rooney, Elaine L Shelton, Ida Aka, Christian M Shaffer, Ronald I Clyman, John M Dagle, Kelli Ryckman, Tamorah R Lewis, Jeff Reese, Sara L Van Driest, Prince J Kannankeril
{"title":"CYP2C9*2 与吲哚美辛治疗动脉导管未闭失败有关。","authors":"Sydney R Rooney, Elaine L Shelton, Ida Aka, Christian M Shaffer, Ronald I Clyman, John M Dagle, Kelli Ryckman, Tamorah R Lewis, Jeff Reese, Sara L Van Driest, Prince J Kannankeril","doi":"10.2217/pgs-2019-0079","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). <b>Patients & Methods:</b> This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. <b>Results:</b> In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and <i>CYP2C9*2</i> (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. <b>Conclusion:</b> Age, surfactant use, and <i>CYP2C9*2</i> influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.</p>","PeriodicalId":78777,"journal":{"name":"The Milbank Memorial Fund quarterly","volume":"36 1 1","pages":"939-946"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817966/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>CYP2C9*2</i> is associated with indomethacin treatment failure for patent ductus arteriosus.\",\"authors\":\"Sydney R Rooney, Elaine L Shelton, Ida Aka, Christian M Shaffer, Ronald I Clyman, John M Dagle, Kelli Ryckman, Tamorah R Lewis, Jeff Reese, Sara L Van Driest, Prince J Kannankeril\",\"doi\":\"10.2217/pgs-2019-0079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). <b>Patients & Methods:</b> This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. <b>Results:</b> In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and <i>CYP2C9*2</i> (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. <b>Conclusion:</b> Age, surfactant use, and <i>CYP2C9*2</i> influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.</p>\",\"PeriodicalId\":78777,\"journal\":{\"name\":\"The Milbank Memorial Fund quarterly\",\"volume\":\"36 1 1\",\"pages\":\"939-946\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817966/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Milbank Memorial Fund quarterly\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2019-0079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Milbank Memorial Fund quarterly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2019-0079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的：确定与吲哚美辛治疗早产儿动脉导管未闭（PDA）失败相关的临床和遗传因素。患者和方法：这是一项多中心队列研究，在三个中心对 144 名早产儿（胎龄 22-32 周）进行了研究，这些早产儿至少接受过一个疗程的吲哚美辛治疗 PDA。吲哚美辛治疗失败的定义是随后需要手术干预。结果在多变量分析中，胎龄（AOR 0.76，95% CI 0.60-0.96）、表面活性物质的使用（AOR 9.77，95% CI 1.15-83.26）和 CYP2C9*2 （AOR 3.74；95% CI 1.34-10.44）均与吲哚美辛失败有关。结论年龄、表面活性物质的使用和 CYP2C9*2 会影响 PDA 早产儿的吲哚美辛治疗效果。临床和遗传因素的结合可能有助于有针对性地使用吲哚美辛治疗 PDA。
CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus.
Aims: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). Patients & Methods: This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. Results: In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and CYP2C9*2 (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Conclusion: Age, surfactant use, and CYP2C9*2 influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
